Definium Therapeutics (DFTX) had the highest return this year and in June 2026 by a mid-cap US stock, returning 95.5%.
| ASSET | % RETURN |
|---|---|
Definium Therapeutics (DFTX) | 95.51% |
Butterfly Network (BFLY) | 89.64% |
Newell Brands (NWL) | 80.06% |
MBX Biosciences, Inc Common Stock (MBX) | 76.08% |
Ultra Clean (UCTT) | 71.96% |
Oruka Therapeutics (ORKA) | 65.43% |
Uniqure (QURE) | 64.97% |
Sellas Life Sciences (SLS) | 62.38% |
Ichor (ICHR) | 61.72% |
Victoria's Secret (VSXY) | 59.74% |
Alignment Healthcare LLC (ALHC) | 56.03% |
Twist Bioscience (TWST) | 53.85% |
Acm Research (ACMR) | 51.96% |
Enova International (ENVA) | 50.34% |
Compass (COMP) | 50.18% |
Allegro Microsystems (ALGM) | 47.42% |
PDF Solutions (PDFS) | 47.17% |
TG Therapeutics (TGTX) | 46.31% |
Sezzle (SEZL) | 46.18% |
Hinge Health (HNGE) | 44.73% |
Tango Therapeutics (TNGX) | 43.66% |
Cohu (COHU) | 43.26% |
Adaptive Biotechnologies (ADPT) | 43.1% |
Fortune Brands Innovations (FBIN) | 43.04% |
Kymera Therapeutics (KYMR) | 42.16% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.